Compare Globus Medical Inc. Class A Common Stock (GMED) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs ING Groep NV — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while ING Groep NV trades at $33.34 (market cap $94.92B). The key difference: ING Groep NV is far larger — about 9.3× Globus Medical Inc. Class A Common Stock's market cap, and ING Groep NV pays a 3.93% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and ING Groep NV for 94 Days on average.
| GMED | ING | |
|---|---|---|
Market Cap | $10.25B | $94.92B |
Volume | 1,108,124 | 2,055,666 |
Sector | Health | Financials |
52-Week High | $96.82 | $37.27 |
52-Week Low | $58.33 | $23.66 |
Typical Hold Time | 0 Days | 94 Days |
Enterprise Value | $9.76B | $237.77B |
Dividend Yield | — | 3.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
ING trades at $33.63, up 0.72% today, with a bearish technical signal but strong fundamentals including a 28.34% net income margin and consistent earnings beats. Recent news highlights management's raised ROE target above 16% for 2027, driven by revenue growth and AI initiatives. Cash flow trends show volatile net outflows, with 2025 net cash flow at -$14.92 billion.
The outlook is mixed: analyst consensus is bullish with 65% buy ratings, but technical indicators and cash flow volatility pose risks. Upside potential hinges on execution of growth strategies and cost discipline, while regulatory scrutiny and macroeconomic pressures remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
